Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
Conditions: Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast CancerInterventions: Drug: tamoxifen citrate; Drug: anastrozole; Drug: letrozole; Drug: exemestane; Radiation: radiation therapy; Other: laboratory biomarker analysis; Other: quality-of-life assessmentSponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; NSABP Foundation Inc; Cancer and Leukemia Group B; Southwest Oncology Group; NCIC Clinical Trials Group; American College of SurgeonsActive, not recruiting - verified June 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Arimidex | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | HER2 | Hormonal Therapy | Hormones | Research | Women